[
  {
    "ts": null,
    "headline": "Gilead Sciences, Inc. (GILD)’s Mixed Quarter Draws Divergent Analyst Views",
    "summary": "Gilead Sciences, Inc. (NASDAQ:GILD) is one of the best blue-chip stocks to buy now. On November 3, Bernstein SocGen Group reiterated its “Outperform” rating on Gilead Sciences, Inc. (NASDAQ: GILD), setting a price target of $135. The firm highlighted the company’s solid third-quarter performance and noted continued strength in HIV therapies and emerging treatments as […]",
    "url": "https://finnhub.io/api/news?id=5e330fd2031c364586e5686b07fc86421b23d18807158a4dfbd6631ab948d6cc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763182253,
      "headline": "Gilead Sciences, Inc. (GILD)’s Mixed Quarter Draws Divergent Analyst Views",
      "id": 137486726,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Gilead Sciences, Inc. (NASDAQ:GILD) is one of the best blue-chip stocks to buy now. On November 3, Bernstein SocGen Group reiterated its “Outperform” rating on Gilead Sciences, Inc. (NASDAQ: GILD), setting a price target of $135. The firm highlighted the company’s solid third-quarter performance and noted continued strength in HIV therapies and emerging treatments as […]",
      "url": "https://finnhub.io/api/news?id=5e330fd2031c364586e5686b07fc86421b23d18807158a4dfbd6631ab948d6cc"
    }
  }
]